Breaking News

OctoPlus Inks Delivery Pact with U.S. Biotech

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus' controlled release technology.

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus’ controlled release technology. OctoPlus will use its PolyActive drug delivery technology to develop a controlled release version of a product currently in clinical development.

Simon Sturge, chief executive officer of OctoPlus, said, “I am delighted to see the continued adoption of our PolyActive technology. We continue to explore opportunities where OctoPlus’ unique skills in microsphere development and production can be best exploited.” Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters